463 patents
Page 15 of 24
Utility
TLX and MIR-219 as potential therapeutic targets for neurodevelopmental disorders
25 May 21
Disclosed herein are methods of treating neurodevelopmental disorders such as schizophrenia (SCZ), bipolar disorder or depression.
Yanhong Shi
Filed: 10 Mar 17
Utility
Treatment device for plasma virus inactivation
25 May 21
A device and method can be used for clinical virus inactivation treatment to automatically, continuously and cyclically treat plasma of a patient in a closed system.
Yuwen Huang, Qin Mo, Bo Zhang, Kaicheng Qian, Yongming Zhu, Shirong Wang, Xun Wang, Xiaofei Wu, Yao Jia, Lidong Liu
Filed: 19 Nov 15
Utility
Chemically encoded spatially addressed library screening platforms
25 May 21
Provided herein are encoded split pool libraries useful, inter alia, for forming highly diverse and dense arrays for screening and detection of a variety of molecules.
Jacob Berlin, Gregory Copeland, Kathleen Elison, Hurik Muradyan
Filed: 28 Jul 20
Utility
Chemically encoded spatially addressed library screening platforms
25 May 21
Provided herein are encoded split pool libraries useful, inter alia, for forming highly diverse and dense arrays for screening and detection of a variety of molecules.
Jacob Berlin, Gregory Copeland, Kathleen Elison, Hurik Muradyan
Filed: 30 Jul 20
Utility
System, Device and Method for Production of Bioproduct Including High Density Cell Respirator (HDCR) for Intensified Production of Adeno-associated Viruses (Aav) and Cell-based Production
20 May 21
A cell cultivation apparatus for cultivating microorganisms and growing cells at high density is provided.
Colin Andrew Cook, Yuman Fong, Yu-Chong Tai, Saswati Chatterjee
Filed: 13 Nov 20
Utility
Method of Controlling Administration of Cancer Antigen
20 May 21
The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells.
Laurence J.N. Cooper, Michael C. Jensen
Filed: 2 Jul 20
Utility
T-cell Lymphoma Treatments
20 May 21
Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound.
David Horne, Sangkil Nam
Filed: 15 Jun 18
Utility
Phosphorothioate-conjugated Peptides and Methods of Using the Same
20 May 21
Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein attached at its C-terminus to a phosphorothioate nucleic acid.
Andreas HERRMANN, Hua YU, Toshikage NAGAO
Filed: 13 Jul 18
Utility
CCR7 aptamers and uses thereof
18 May 21
Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells.
John Rossi, Jiehua Zhou, Mayumi Takahashi
Filed: 4 Jan 19
Utility
Pyridopyrazine Compounds and Uses Thereof
13 May 21
Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.
Sangkil Nam, David Horne, Ravi Salgia, Alexios-Leandros Skaltsounis, Nikolaos Lougiakis, Nicole Pouli, Panagiotis Marakos
Filed: 21 Jun 18
Utility
Methods of Stromal Cell Expansion, Uses and Materials Related Thereto
6 May 21
Disclosed herein are methods for expanding and potentiating intra-pancreatic tissue-derived mesenchymal stromal/stem cells in the presence of TNF-α, DMOG, or both, to obtain IPTD-MSCs having enhanced pro-angiogenic and/or anti-inflammatory properties.
Ismail H. AL-ABDULLAH, Meirigeng QI, Hsun Terasa KU, Bashar KHIATAH
Filed: 28 Oct 20
Utility
CTLA4-BINDING Protein Peptide-linker Masks
29 Apr 21
Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer.
John WILLIAMS, Ulrich RODECK
Filed: 13 May 20
Utility
CONDITIONAL-siRNAS AND USES THEREOF IN TREATING ACUTE MYELOID LEUKEMIA
29 Apr 21
Disclosed herein are conditional siRNAs activatable by CBFβ-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML).
Guido MARCUCCI, Ya-Huei KUI, Si-ping HAN, Lisa SCHERER, William A. GODDARD, III, John ROSSI
Filed: 10 Feb 20
Utility
Synthetic conjugate of CpG DNA and T-help/CTL peptide
27 Apr 21
Highly effective vaccine compositions are constructed according to the methods of this invention.
Don J. Diamond
Filed: 6 Feb 20
Utility
Phosphorothioate-conjugated miRNAs and methods of using the same
27 Apr 21
Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3′ end to a phosphorothioate polymer.
Andreas Herrmann, Hua Yu
Filed: 3 Jun 19
Utility
Use of Triplex CMV Vaccine in CAR T Cell Therapy
22 Apr 21
A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE I (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.
Don J. Diamond
Filed: 28 Aug 20
Utility
Epstein-barr Virus Antibodies and Uses Thereof
22 Apr 21
Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more immunogenic peptides.
Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA
Filed: 27 Jul 20
Utility
Dithio Etp Derivatives
22 Apr 21
Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.
Sangkil Nam, David Horne, Larry Eugene Overman, Brad Loertscher
Filed: 23 Sep 20
Utility
Compounds and Compositions Including Phosphorothioated Oligodeoxynucleotide, and Methods of Use Thereof
22 Apr 21
The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
Filed: 2 Sep 20
Utility
Methods for Preparing Cells for Adoptive T Cell Therapy
8 Apr 21
An improved method for preparing T cell populations expressing a chimeric antigen receptor is described.
Stephen J. Forman, Xiuli Wang
Filed: 10 Aug 20